Proactive Investors - Run By Investors For Investors

Sareum selects potential anti-cancer molecule for further development

Sareum has now chosen two molecules from its TYK2 inhibitor programme for further development, one as a potential treatment for autoimmune disease and the other for certain types of cancer
scientist with test tubes
In-human clinical trials of the two compounds could happen as early as 2020

Sareum Holdings Plc (LON:SAR) has selected another candidate molecule from its TYK2 inhibitor programme to take through the clinic, this time as a potential therapy for certain cancers.

Earlier this month, the AIM company went with SDC-1801 as a “potentially best-in-class” treatment for autoimmune diseases.

READ: Sareum to further develop ‘potential best-in-class’ autoimmune disease treatment

It has now chosen SDC-1802 which has shown “compelling efficacy” in blocking cancer cell proliferation in leukaemia disease models, while Sareum thinks it could also be used to treat certain kidney, colon, skin and pancreatic cancers.

The compound has the potential for once-daily oral dosing and a good early safety profile, Sareum added.

SDC-1802 works by targeting the TYK2 and JAK1 enzymes, which are known to have roles in promoting cancer growth.

Those enzymes are also involved in the pro-inflammatory responses in autoimmune diseases, which is why Sareum thinks SDC-1802 also has the potential to act as a backup molecule to SDC-1801.

Clinical trials in 2020

“We are very pleased to have formally selected lead candidates from our TYK2 inhibitor programme for both cancer and autoimmune diseases,” said chief executive Tim Mitchell.

“The candidates are distinct small molecules with attractive and highly competitive profiles for development in their respective indications.”

He added: “Both have produced exciting results in preclinical disease models and we believe present valuable opportunities for licensing and/or further development.

“Our focus is now to advance both candidates into clinical studies, which we anticipate beginning in 2020.”

Sareum shares were down 1.3% to 0.76p shortly after the opening bell on Wednesday.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Big Picture
February 22 2019

Related Articles

Hep C
November 22 2018
The company made positive operational progress in the year to June 30.
November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use